Lai Mei Pharmaceutical: Obtained the approval notice for the supplementary application of naloxone hydrochloride injection.

Lai Mei Pharmaceuticals announced on the evening of May 12 that the company has recently received approval from the National Medical Products Administration for the issuance of two specifications of naloxone hydrochloride injection: 1ml:1mg and 2ml:2mg. As an emergency drug that has been used in clinical applications for many years, naloxone hydrochloride injection has been included in the 2024 National Medical Insurance Category A Drug List. Obtaining the "Drug Supplementary Application Approval Notice" for naloxone hydrochloride injection will enhance the market competitiveness of this product and facilitate its future market expansion.